MGC Pharmaceuticals Limited Appointment of Non-Executive Director (3212B)
June 01 2023 - 2:30AM
UK Regulatory
TIDMMXC
RNS Number : 3212B
MGC Pharmaceuticals Limited
01 June 2023
1 June 2023
ASX Code: MXC
LSE Code: MXC
Appointment of Non-Executive Director
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a
European based pharmaceutical company specialising in the
production and development of plant inspired medicines, is pleased
to announce the appointment of Mr. Layton Mills as a Non-Executive
Director of the Company effective immediately.
Mr. Mills is an experienced life-sciences executive, having
worked in the biotechnology and life sciences industries for over
15 years, developing significant experience across human and animal
health in pharmaceutical and consumer healthcare.
Mr. Mills is the founder of CannPal Animal Therapeutics Pty Ltd,
an Animal Health Company developing cannabinoid-based veterinary
medicines for FDA-CVM registration, which he led through an Initial
Public Offering on the Australian Stock Exchange, followed by an
acquisition by AusCann Group Holdings in 2021 where he served as
CEO. Mr Mills is also the founder and Managing Director of Subgenix
Lifesciences, an early-stage biotechnology Company using
conventional drug development strategies to unlock the broader
therapeutic potential of psychedelic compounds for rare and
underserved health needs .
He has extensive international business experience having been
involved in corporate business activities across Europe, Asia and
North America, including government-led trade incentives with the
Canberra Business Chamber.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais / Rowan Harland
CEO & Managing Director Joint Company Secretaries
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK Brokers UK Brokers
Peterhouse Capital Oberon Capital
Charles Goodfellow / Lucy Williams Aimee McCusker / Adam Pollock
/ Duncan Vasey +44 203 179 5300
+44 207 469 0930 aimeemccusker@oberoninvestments.com
cg@peterhousecap.com / lw@peterhousecap.com adampollock@oberoninvestments.com
UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe /
Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant inspired medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZZGGVVMGGFZG
(END) Dow Jones Newswires
June 01, 2023 02:30 ET (06:30 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Jul 2023 to Jul 2024